Benutzer: Gast  Login
Titel:

Conventional chemotherapy (CHOEP-14) with rituximab or high-dose chemotherapy (MegaCHOEP) with rituximab for young, high-risk patients with aggressive B-cell lymphoma: an open-label, randomised, phase 3 trial (DSHNHL 2002-1).

Dokumenttyp:
journal article
Autor(en):
Schmitz, N; Nickelsen, M; Ziepert, M; Haenel, M; Borchmann, P; Schmidt, C; Viardot, A; Bentz, M; Peter, N; Ehninger, G; Doelken, G; Ruebe, C; Truemper, L; Rosenwald, A; Pfreundschuh, M; Loeffler, M; Glass, B; German High-Grade Lymphoma Study Group (DSHNHL); Sezer, O; Ordemann, R; Behringer, D; Brossart, P; Fritsch, G; Pflüger, KH; Hänel, M; Peter, N; Levknecht, C; Ehninger, G; Schlegel, F; Dührsen, U; Weidmann, E; Kiehl, M; Giagounidis, A; Trümper, L; Dölken, G; Lindemann, HW; Appel, T; Schmoll,...     »
Abstract:
High-dose therapy (HDT) followed by transplantation of autologous haemopoietic stem cells is frequently done as part of first-line therapy in young patients with high-risk aggressive B-cell lymphoma. We investigated whether HDT with cytotoxic agents identical to those used for conventional therapy followed by autologous stem-cell transplantation (ASCT) improved survival outcome compared with conventional chemotherapy when rituximab was added to both modalities.We did an open-label, randomised tr...     »
Zeitschriftentitel:
Lancet Oncol
Jahr:
2012
Band / Volume:
13
Heft / Issue:
12
Seitenangaben Beitrag:
1250-9
Sprache:
eng
PubMed:
http://view.ncbi.nlm.nih.gov/pubmed/23168367
Print-ISSN:
1470-2045
TUM Einrichtung:
III. Medizinische Klinik und Poliklinik
 BibTeX